Aligos Therapeutics, Inc. (ALGS) — SEC Filings
Aligos Therapeutics, Inc. (ALGS) — 42 SEC filings. Latest: 10-Q (Nov 6, 2025). Includes 20 8-K, 8 SC 13G/A, 6 10-Q.
View Aligos Therapeutics, Inc. on SEC EDGAR
Overview
Aligos Therapeutics, Inc. (ALGS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Aligos Therapeutics, Inc. reported a net loss of $31.537 million for the three months ended September 30, 2025, a significant increase from the $19.259 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $4.312 million, a substantial improvemen
Sentiment Summary
Across 42 filings, the sentiment breakdown is: 3 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Aligos Therapeutics, Inc. is neutral.
Filing Type Overview
Aligos Therapeutics, Inc. (ALGS) has filed 6 10-Q, 20 8-K, 2 DEF 14A, 2 10-K, 8 SC 13G/A, 3 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (42)
Risk Profile
Risk Assessment: Of ALGS's 28 recent filings, 4 were flagged as high-risk, 12 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $741K |
| Net Income | -$31.537M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $41.946M |
| Operating Margin | N/A |
| Total Assets | $109.764M |
| Total Debt | $0 |
Key Executives
- Dr. David P. Gryaznov
- Ms. Jennifer L. D. Fox
- Dr. Michael Y. Lin
- Lawrence M. Blatt, Ph.D.
- Max Eisenberg
Industry Context
Aligos Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on developing treatments for viral diseases and liver diseases. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies like Aligos rely heavily on innovation and successful clinical trial outcomes to advance their pipelines and secure funding.
Top Tags
financial-reporting (5) · sec-filing (4) · 10-Q (4) · biotech (4) · Biotechnology (3) · 8-k (3) · licensing (3) · Net Loss (2) · R&D Expenses (2) · corporate-governance (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $31.537M | Increased from $19.259M in Q3 2024, indicating widening operational losses. |
| Net Loss (YTD Q3 2025) | $4.312M | Significantly improved from $49.061M in YTD Q3 2024, primarily due to warrant revaluation. |
| Change in Fair Value of Warrants (YTD Q3 2025) | $58.971M | A non-cash gain that substantially reduced the reported YTD net loss. |
| Research and Development Expenses (Q3 2025) | $23.937M | Increased from $16.774M in Q3 2024, reflecting ongoing pipeline investment. |
| Additional Paid-in Capital (YTD Q3 2025) | $105.003M | Resulted from the 2025 PIPE offering, significantly boosting equity. |
| Cash and Cash Equivalents (Sept 30, 2025) | $41.946M | Increased from $36.997M at Dec 31, 2024, providing short-term liquidity. |
| Accumulated Deficit (Sept 30, 2025) | $622.320M | Reflects substantial historical losses since inception. |
| Total Stockholders' Equity (Sept 30, 2025) | $71.833M | Shifted from a deficit of $28.973M at Dec 31, 2024, due to the PIPE offering. |
| Revenue from Customers (Q3 2025) | $741K | Decreased from $1.250M in Q3 2024, highlighting lack of product sales. |
| Common Shares Outstanding (Sept 30, 2025) | 6,153,507 | Increased from 3,864,436 at Dec 31, 2024, indicating dilution from capital raises. |
| Net Loss | $18.5M | for the three months ended June 30, 2025, indicating continued operational losses. |
| R&D Expenses | $14.2M | for the three months ended June 30, 2025, showing significant investment in pipeline development. |
| Gross Proceeds | $1.0M | from February 2025 PIPE offering, providing limited capital for ongoing operations. |
| Revenue | 0 | for the three and six months ended June 30, 2025, highlighting the company's pre-commercial status. |
| Reporting Period End Date | 2025-03-31 | Covers financial and operational data up to this date. |
Frequently Asked Questions
What are the latest SEC filings for Aligos Therapeutics, Inc. (ALGS)?
Aligos Therapeutics, Inc. has 42 recent SEC filings from Jan 2024 to Nov 2025, including 20 8-K, 8 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ALGS filings?
Across 42 filings, the sentiment breakdown is: 3 bearish, 38 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Aligos Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Aligos Therapeutics, Inc. (ALGS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Aligos Therapeutics, Inc.?
Key financial highlights from Aligos Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ALGS?
The investment thesis for ALGS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Aligos Therapeutics, Inc.?
Key executives identified across Aligos Therapeutics, Inc.'s filings include Dr. David P. Gryaznov, Ms. Jennifer L. D. Fox, Dr. Michael Y. Lin, Lawrence M. Blatt, Ph.D., Max Eisenberg.
What are the main risk factors for Aligos Therapeutics, Inc. stock?
Of ALGS's 28 assessed filings, 4 were flagged high-risk, 12 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Aligos Therapeutics, Inc.?
Forward guidance and predictions for Aligos Therapeutics, Inc. are extracted from SEC filings as they are enriched.